BioWorld

Dec. 23, 2008

View Archived Issues

Two Aussie Biotechs Merging to Focus on Phase III HIV Dru

Australian biotech firms Progen Pharmaceuticals Ltd. and Avexa Ltd. have agreed to merge, creating a new company with a well-funded oncology and HIV pipeline. (BioWorld Today) Read More

Obama Reveals Top Science Advisers and NOAA Chief

Read More

NPS Launches Pivotal Study of NPSP558 in Hypoparathyroidism

Read More

Amgen Files BLA for Denosumab in Bone Loss; No Partners (Yet?)

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More

Financings Roundup

Read More